J&J to step up investment in R&D and training in China

Pharma giant inks deal with Shanghai hospital

Johnson & Johnson, the US pharmaceuticals, medical devices and consumer products giant, has signed a memorandum of understanding with Shanghai Ruijin Hospital to collaborate on translational research, or the turning of scientific findings into practical applications.

The MoU was agreed upon at the start of the month by Janssen Pharmaceutical, J&J's pharmaceuticals arm, at the opening of the National Translational Medicine Center at Ruijin Hospital. The collaboration will center on bringing some of the best science and technology to China, said William Hait, global head, research and development at Janssen.